CAMBRIDGE, Mass.--(BUSINESS WIRE)--Semma Therapeutics, Inc., a biotechnology company pioneering the curative use of stem cells in regenerative medicine, today announced that it has expanded its leadership team with the addition of Mary Kay Fenton as Chief Financial Officer.
“I am absolutely thrilled to welcome Mary Kay to our team. She will not only help us to streamline and optimize our operations, but further expand our ability to execute on our strategic vision to deliver a functional cure for patients living with Type 1 diabetes,” said Bastiano Sanna, Ph.D., Chief Executive Officer and President, Semma Therapeutics. “Mary Kay’s extensive experience in funding emerging biotech companies at both private and public stages will allow us to sustain Semma through our next phase of growth as a clinical-stage company.”
Ms. Fenton brings decades of experience working with fast-growing biotech companies, most recently as Executive Vice President and Chief Financial Officer of Achillion Pharmaceuticals, a biopharmaceutical company developing therapies for immune system disorders. At Achillion, Ms. Fenton was a key member of the executive team and was instrumental in all phases of the company’s growth, including successfully raising multiple rounds of public and private capital, and leading financial and operational functions. Prior to joining Achillion, Ms. Fenton was with PricewaterCoopers LLP, where she led the emerging bioscience practice in Connecticut.
“Despite the discovery of insulin almost a century ago, insulin injections remain the only treatment available to patients living with Type 1 diabetes,” said Mary Kay Fenton, Chief Financial Officer, Semma Therapeutics. “Semma is poised to radically change the way of life for millions of people around the world living with the disease, and I look forward to lending my financial expertise and passion for great science to help the company fully realize its potential as a leader in regenerative cell therapy.”
About Semma Therapeutics
Semma Therapeutics is pioneering
the new treatment paradigm of using cells as medicine. Semma’s new class
of regenerative medicine therapies couples its breakthrough stem cell
technologies with proprietary delivery systems designed to protect cells
from the immune system. Ongoing research at Semma Therapeutics is
focused on combining these highly-differentiated active cells with a
state-of-the-art device to provide a functional cure for patients with
diabetes. Semma Therapeutics is working to bring new therapeutic options
to the clinic and improve the lives of patients. The company is
headquartered in Cambridge, MA, with operations in Providence, RI. For
more information, visit www.semma-tx.com.
